Ukraine, Belarus, Azerbaijan and Moldova demand that Johnson & Johnson take urgent action to improve equitable access to bedaquiline in all countries with a high burden of TB.

Advocates demand that Johnson & Johnson commit to non-enforcement of secondary patent on bedaquiline so that access to generic, quality-assured bedaquiline is guaranteed after the primary patent expires on 18 July 2023.

Advocates urge Cepheid to take immediate action necessary to bring about affordable, equitable, and expanded access to GeneXpert TB testing.

Advocates urge Johnson & Johnson to correct its course and stop blocking entry of generic versions of bedaquiline into the global market and into countries.

Advocates urge the Indian government to stop using kanamycin for the treatment of drug-resistant TB and instead scale up access to all oral regimens.

Advocates request Cepheid immediately reduce the price of Xpert tests to $5, inclusive of service and maintenance; Cepheid claims costs for each Xpert cartridge "substantially exceed" the requested price target of $5, but does not provide evidence to support this claim.

Pretomanid receives FDA approval in combination regimen with bedaquiline and linezolid for people with XDR-TB or treatment-intolerant/non-responsive MDR-TB.

Advocates request responsible investment in pretomanid promoting transparency and equitable access.

Activists storm the corporate stall of Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson) at the 9^th South African AIDS Conference.

Advocates request full access to the terms of the agreement granting Mylan the rights to commercialize pretomanid.